International Journal of Medicine and Data

Objective To investigate the effect and mechanism of cyclobenzaprine in improving neurological dysfunction after ischemic stroke by inhibiting NLRP3 inflammatory vesicles. Methods A total of 40 patients with ischemic stroke diagnosed in 2023 were included in this study and randomly divided into two groups (n=20). The control group received standardized basic treatment, and the experimental group added cyclobenzaprine (0.5-1.0 mg/kg administered intravenously) to the basic treatment for 2 weeks. Observation indexes included the degree of neurological deficit (NIHSS score), the ability to perform activities of daily living (ADL score) and serum NLRP3 level. Results After treatment, the NIHSS score of the treatment group was significantly lower than that of the control group (P<0.05), the ADL score was significantly higher than that of the control group (P<0.05), and the serum NLRP3 level was significantly lower (P<0.05), and the difference of each index before treatment was not statistically significant (P>0.05). Conclusion Cypropofol can significantly improve neurological dysfunction after ischemic stroke, which may be related to the inhibition of NLRP3 inflammatory vesicle activation, providing new evidence for clinical application, but large-sample, long-term follow-up studies are still needed to validate its effectiveness and safety.

Cyclopoietin; Ischemic stroke; Neurological deficits; NLRP3